- Home
- PGNY
PGNY
Progyny Inc.
as 02-21-2025 4:00pm EST
Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.
Upcoming Earnings Alert:
Get ready for potential market movements as Progyny Inc. PGNY prepares to release earnings report on 27 Feb 2025.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 1.9B | IPO Year: | 2019 |
| Target Price: | $20.83 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.60 | EPS Growth: | 17.45 |
| 52 Week Low/High: | $13.39 - $40.89 | Next Earning Date: | 02-27-2025 |
| Revenue: | $1,138,730,000 | Revenue Growth: | 10.24% |
| Revenue Growth (this year): | 7.39% | Revenue Growth (next year): | 1.11% |
Stock Insider Trading Activity of Progyny Inc. (PGNY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Schlanger David J | PGNY | Executive Chairman | Dec 26 '24 | Buy | $14.68 | 150,000 | $2,202,330.00 | 228,269 | |
| Anevski Peter | PGNY | CHIEF EXECUTIVE OFFICER | Dec 23 '24 | Buy | $14.48 | 209,500 | $3,034,083.75 | 441,463 |
Latest Progyny Inc. News
PGNY Breaking Stock News: Dive into PGNY Ticker-Specific Updates for Smart Investing
TipRanks
2 days ago
Progyny price target raised to $30 from $25 at BofA
Zacks
2 days ago
Progyny (PGNY) Reports Next Week: Wall Street Expects Earnings Growth
Argus Research
4 days ago
PGNY: Rating increased to a HOLD
Simply Wall St.
4 days ago
Is Progyny, Inc.'s (NASDAQ:PGNY) Recent Stock Performance Tethered To Its Strong Fundamentals?
GlobeNewswire
9 days ago
Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2024 Results Report
MT Newswires
17 days ago
Truist Securities Adjusts Progyny Price Target to $24 From $19, Maintains Hold Rating
Argus Research
18 days ago
PGNY: What does Argus have to say about PGNY?
Zacks
19 days ago
All You Need to Know About Progyny (PGNY) Rating Upgrade to Buy
Compare PGNY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PGNY Progyny Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.